Galapagos NV has received non-binding offers from consortia interested in acquiring its cell therapy business. The company is supporting potential bidders as they conduct due diligence and assess financing options, with binding offers expected soon. The Board of Directors initiated a strategic review on May 13, 2025, with a decision on divestment or alternative strategies to be made following binding offers. The outcome of this review will be announced by November 5, 2025, alongside third-quarter financial results.

Read more at Nasdaq: Galapagos Receives Non-Binding Offers For Cell Therapy Business